Non-Compliance Report for Indian API manufacturer

Recommendation
16-18 September 2025
Barcelona, Spain
Organisation of a GMP-compliant Site Change
During an inspection in March 2018, the French competent authority discovered various GMP violations at the site of an Indian manufacturer. The manufactured product was a beta-lactam antibiotic. The manufacturing steps drying, milling and blending had been inspected as well as the primary and secondary packaging. The quality control for physical/chemical and microbiological testing had also been part of the inspection.
Overall, 24 deficiencies were found, one of which had been classified as critical and eight as major. The critical deficiency observed concerned multiple cross contamination risks. The deficiencies listed in the category "major" were about:
- Insufficient CAPA management
- Insufficient maintenance of facilities
- Lacking control of water quality
- Various deficits in the area of equipment and its maintenance
- Insufficient storage management
- Various validation deficits
- Failing change control management system
As a consequence, the risk-based recall of all batch produced at the facility should be considered. Furthermore, the EDQM should consider withdrawing the CEP.
Source: EMA EudraGMDP database
Related GMP News
03.07.2025The USP has revised the General Chapter <1231> on Pharmaceutical Water
25.06.2025Deficiencies in the Water System: Warning Letter to US Manufacturers of OTC Products
11.06.2025Warning Letter to Chinese Manufacturer due to serious Sterility and Hygiene Deficiencies
04.06.2025FAQs regarding Cross Contamination
04.06.2025GMP Deficiencies at French Sterile Manufacturer
14.05.2025Process Validation and Pharmaceutical Water Deficiencies at a US Manufacturer